502 related articles for article (PubMed ID: 19667590)
1. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP
Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
[TBL] [Abstract][Full Text] [Related]
2. Barriers to the effective management of respiratory tract infections in the community.
Saginur R
Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
Brixner DI
Am J Manag Care; 2004 Oct; 10(12 Suppl):S400-7. PubMed ID: 15603249
[No Abstract] [Full Text] [Related]
4. Novel agents for the treatment of outpatient respiratory tract infections. Introduction.
Pell DM
Postgrad Med; 2002 Sep; 112(3 Suppl):5-6. PubMed ID: 19667592
[No Abstract] [Full Text] [Related]
5. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Martin M; Moore L; Quilici S; Decramer M; Simoens S
Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
[TBL] [Abstract][Full Text] [Related]
6. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial treatment of lower respiratory tract infections in the hospital setting.
Grossman RF; Rotschafer JC; Tan JS
Am J Med; 2005 Jul; 118 Suppl 7A():29S-38S. PubMed ID: 15993675
[TBL] [Abstract][Full Text] [Related]
8. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
Mokabberi R; Haftbaradaran A; Ravakhah K
J Clin Pharm Ther; 2010 Apr; 35(2):195-200. PubMed ID: 20456738
[TBL] [Abstract][Full Text] [Related]
9. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
Segreti J; House HR; Siegel RE
Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
[TBL] [Abstract][Full Text] [Related]
10. Meeting the challenge of antibiotic resistance: The PROTEKT US study.
Stratton CW
Postgrad Med; 2002 Sep; 112(3 Suppl):7-11. PubMed ID: 19667589
[TBL] [Abstract][Full Text] [Related]
11. Levofloxacin in the treatment of community-acquired pneumonia.
Noreddin AM; Elkhatib WF
Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679
[TBL] [Abstract][Full Text] [Related]
12. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
Charles PG; Whitby M; Fuller AJ; Stirling R; Wright AA; Korman TM; Holmes PW; Christiansen KJ; Waterer GW; Pierce RJ; Mayall BC; Armstrong JG; Catton MG; Nimmo GR; Johnson B; Hooy M; Grayson ML;
Clin Infect Dis; 2008 May; 46(10):1513-21. PubMed ID: 18419484
[TBL] [Abstract][Full Text] [Related]
13. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
[TBL] [Abstract][Full Text] [Related]
14. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
Cantón R; Lode H; Graninger W; Milkovich G
Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.
Lynch III JP; Martinez FJ
Clin Infect Dis; 2002 Mar; 34 Suppl 1():S27-46. PubMed ID: 11810608
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
[TBL] [Abstract][Full Text] [Related]
18. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Samsa GP; Matchar DB; Harnett J; Wilson J
Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
[TBL] [Abstract][Full Text] [Related]
19. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance.
Martin M; Quilici S; File T; Garau J; Kureishi A; Kubin M
J Antimicrob Chemother; 2007 May; 59(5):977-89. PubMed ID: 17395688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
